title: Human hepatocyte growth factor (hHGF)-modified hepatic oval cells improve liver transplant survival.
abstract: Despite progress in the field of immunosuppression, acute rejection is still a common postoperative complication following liver transplantation. This study aims to investigate the capacity of the human hepatocyte growth factor (hHGF) in modifying hepatic oval cells (HOCs) administered simultaneously with orthotopic liver transplantation as a means of improving graft survival. HOCs were activated and isolated using a modified 2-acetylaminofluorene/partial hepatectomy (2-AAF/PH) model in male Lewis rats. A HOC line stably expressing the HGF gene was established following stable transfection of the pBLAST2-hHGF plasmid. Our results demonstrated that hHGF-modified HOCs could efficiently differentiate into hepatocytes and bile duct epithelial cells in vitro. Administration of HOCs at the time of liver transplantation induced a wider distribution of SRY-positive donor cells in liver tissues. Administration of hHGF-HOC at the time of transplantation remarkably prolonged the median survival time and improved liver function for recipients compared to these parameters in the other treatment groups (P<0.05). Moreover, hHGF-HOC administration at the time of liver transplantation significantly suppressed elevation of interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) levels while increasing the production of IL-10 and TGF-β1 (P<0.05). HOC or hHGF-HOC administration promoted cell proliferation, reduced cell apoptosis, and decreased liver allograft rejection rates. Furthermore, hHGF-modified HOCs more efficiently reduced acute allograft rejection (P<0.05 versus HOC transplantation only). Our results indicate that the combination of hHGF-modified HOCs with liver transplantation decreased host anti-graft immune responses resulting in a reduction of allograft rejection rates and prolonging graft survival in recipient rats. This suggests that HOC-based cell transplantation therapies can be developed as a means of treating severe liver injuries.
authors.affiliation: Department of Hepatobiliary Surgery, Liaocheng People's Hospital, Liaocheng, Shandong, China. lllllzhu@126.com
authors.forename: Zhu
authors.initials: Z
authors.lastname: Li
authors.forename: Juan
authors.initials: J
authors.lastname: Chen
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Jiang-Hua
authors.initials: JH
authors.lastname: Ran
authors.forename: Xue-Hua
authors.initials: XH
authors.lastname: Li
authors.forename: Zhi-Heng
authors.initials: ZH
authors.lastname: Liu
authors.forename: Gui-Jie
authors.initials: GJ
authors.lastname: Liu
authors.forename: Yan-Chao
authors.initials: YC
authors.lastname: Gao
authors.forename: Xue-Li
authors.initials: XL
authors.lastname: Zhang
authors.forename: Hiu-Dong
authors.initials: HD
authors.lastname: Sun
mesh_terms: D000818:Animals; D017209:Apoptosis; D049109:Cell Proliferation; D016207:Cytokines / Q000378:metabolism; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival; D017228:Hepatocyte Growth Factor / Q000378:metabolism*; D006801:Humans; D008099:Liver / Q000166:cytology* / Q000378:metabolism / Q000502:physiology; D016031:Liver Transplantation; D008297:Male; D051381:Rats; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000378:metabolism*; D015996:Survival Rate
chemical_list: D016207:Cytokines; D017228:Hepatocyte Growth Factor